LI Fubin
Email: fubin.li@sjtu.edu.cn
Tel: 021-63846590*776624
Research Field:
1) to elucidate how different antibody functions, such as agonistic and pathogenic function, are regulated by antibody intrinsic and extrinsic factors, and to develop novel methods to modulate antibody activity based on the understanding of fundamental principles, including strategies for optimizing agnostic cancer immunotherapeutic antibodies;
2) to understand how protective and autoreactive B cell differentiation is regulated, as well as the function of novel B cell subsets, such as CD11c+ age-associated B cells, and develop B cell-based methods for diagnosis and treatment.
Biography
LI Fubin, Principal investigator of Laboratory of Humoral Immunity and Immunotherapy at Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine. He got a Bachelor's degree in biology from Fudan University in 2001, a Ph.D. in biology from the City University of New York in 2008, and postdoctoral training from Rockefeller University from 2009 to 2013 before joining Shanghai Jiao Tong University School of Medicine. He studies Immunology, focusing on: (1) how the in vivo activities of cancer immunotherapeutic antibodies are regulated and can be optimized; (2) how B cell development and differentiation are regulated. He had published over 20 SCI papers in Science, JEM, PNAS, NC, JI et al., and applied four patent applications, among which two have been used in antibody drug development. His research had been supported by over ten grants from the Chinese central and local government, including the National Overseas High-Level Young Talents Program, the National Science Fund for Excellent Young Scientists and key grant.
Scientific Research Projects
Shanghai Science and Technology Committee (STCSM), STCSM-Experimental Animal Grant, 22140903000, Construction of a new-generation Fc receptor humanized mouse model and its application in the study of intestinal cancer immunotherapy, 2022/03-2025/03
National Natural Science Foundation of China, 82030043, Elucidation of the modes of action and immunotherapeutic effector pathways of monoclonal anti-OX40 antibodies and optimization of antibody design, 2021/01-2025/12
Shanghai Science and Technology Committee (STCSM), STCSM-Preclinical studies of biological and chemical drugs, 19431902900, Preclinical study of novel agonistic antitumor CD40 antibody, 2019/04-2022/03
National Natural Science Foundation of China, 31870924, The impact and mechanism of action of IgG subclass on the pathogenicity of Dsg1-specific autoantibodies in pemphigus foliaceus, 2019/01-2022/12
National Natural Science Foundation of China, 31861143030, Targeting TIGIT-PVR interactions for cancer immunotherapy using monoclonal, 2019/01-2021/12
Ministry of Science and Technology of China, 2018ZX10302301-002, The development of diagnosis strategies and products based on specific immune responses to new M. Tuberculosis antigens, 2018/01-2021/06
Shanghai Science and Technology Committee (STCSM), STCSM-Experimental Animal Grant, 18140902600, The development and application of mice humanized for the target and Fc receptors of monoclonal antibodies, 2018/05-2021/04
Shanghai Municipal Education Commission and Shanghai Education Development Foundation, Shu Guang Scholar, 14SG16, Study of the antitumor activity and mechanism of agonistic Fc-CD40L fusion protein, 2015/01-2017/12
National Natural Science Foundation of China, National Science Fund for Excellent Young Scientists program 31422020, Targeted therapeutic molecules based on antibody Fc, 2015/01 - 2017/12
Ministry of Science and Technology of China program 2014CB943600, Post-transcriptional regulation in lymphocyte development, 2014/01 - 2018/08
National Natural Science Foundation of China, general program 31370934, The Mechanism of driving the anti-tumor activities of agonistic anti-TNFR superfamily member antibodies by inhibitory Fcgamma receptor, 2014/01 - 2017/12
Professor of Special Appointment at Shanghai Institutions of Higher Learning program，2013
National Overseas High Level Young Tanlents Program, 2013
Publications
Chen D, Zhao Y, Li M, Shang H, Li N, Li F, Wang W, Wang Y, Jin R, Liu S, Li X, Gao S, Tian Y, Li R, Li H, Zhang Y, Du M, Cao Y, Zhang Y, Li X, Huang Y, Hu LA, Li F#, Zhang H#. 2021. A general Fc engineering platform for the next generation of antibody therapeutics. Theranostics 11(4):1901-1917 (#co-corresponding) (IF = 8.579)
Zhao R, Zhang H, Zhang Y, Li D, Huang C, Li F. 2020. In Vivo Screen Identifies Zdhhc2 As a Critical Regulator of Germinal Center B Cell Differentiation. Frontiers in Immunology 11:1025 (IF=4.716)
Liu X, Zhao Y, Shi H, Zhang Y, Yin X, Liu M, Zhang H, He Y, Lu B, Jin T, Li F. 2019. Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility. Nature Communications 10(1): 4206. (IF=12.124)
Zhang W, Zhang H, Liu S, Xia F, Kang Z, Zhang Y, Liu Y, Xiao H, Chen L, Huang C, Shen N, Xu H, Li F. 2019. Excessive CD11c+Tbet+ B cells promote aberrant TFH differentiation and affinity-based germinal center selection in lupus. Proceedings of the National Academy of Sciences of the United States of America 116(37):18550-18560. (IF=9.737)
Li M, Lazorchak AS, Ouyang X, Zhang H, Liu H, Arojo OA, Yan L, Jin J, Han Y, Qu G, Fu Y, Xu X, Liu X, Zhang W, Yang Z, Ruan C, Wang Q, Liu D, Huang C, Lu L, Jiang S, Li F#, Su B#. 2019, Sin1/mTORC2 regulate B cell growth and metabolism by activating mTORC1 and Myc. Cellular & Molecular Immunology 16(9):757-769 (#co-corresponding) (IF = 7.551)
Li F#, Smith P, Ravetch JV#. 2014. Inhibitory Fcgamma Receptor Is Required for the Maintenance of Tolerance through Distinct Mechanisms. Journal of immunology 192:3021-8 (#corresponding author) (IF=5.362)
Li F#, Ravetch JV#. 2013. Antitumor activities of agonistic anti-TNFR antibodies require differential FcgammaRIIB coengagement in vivo. Proceedings of the National Academy of Sciences of the United States of America 110: 19501-19506. (#corresponding author) (IF=9.737)
Li F, Ravetch JV. 2012. Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcgamma receptor engagement. Proceedings of the National Academy of Sciences of the United States of America 109: 10966-10971. (IF=9.737)
Li F, Ravetch JV. 2011. Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 333:1030-1034. (IF=31.201)
Li F, Yan Y, Pieretti J, Feldman DA, Eckhardt LA. 2010. Comparison of identical and functional Igh alleles reveals a nonessential role for Emu in somatic hypermutation and class-switch recombination. Journal of immunology 185:6049-6057. (IF=5.745)
Li F, Eckhardt LA. 2009. A role for the IgH intronic enhancer E mu in enforcing allelic exclusion. The Journal of experimental medicine 206:153-167. (IF=14.505)
Patent
Fubin Li, Xiaoyong Fan, Yuan Jiang, Fucan Xia, Shujun Liu, Jiarui Li, Yan Zhang, Huihui Zhang, Anti-CFP10 antibody and its application, Chinese patent application number: 202110904190.X
Fubin Li, Xiaoyong Fan, Yuan Jiang, Fucan Xia, Shujun Liu, Jiarui Li, Yan Zhang, Huihui Zhang, Anti-LAM antibody and its application, Chinese patent application number: 202110902701.4
Fubin Li, Yanxia Bi, Yan Zhang, Huihui Zhang, 2020, Anti-Dsg1 antibody and its application, Chinese patent application number: 202011408005.X.
Fubin Li, Yan Zhang, Mi Zhang, Yanxia Bi, Shihao Tian, Huihui Zhang, Shujun Liu, Fc region of antibodies with enhanced affinity for FcγRIIB, PCT/CN2020/133685
Fubin Li, Yingjie Zhao, Xiaobo Liu, Yan Zhang, Huan Shi, Huihui Zhang, Antibody activity modification and its screening method, Chinese patent application number: 201910895015.1.
Fubin Li, Xiaobo Liu, Yan Zhang, Yingjie Zhao, Huan Shi, Huihui Zhang, Sequences of heavy chain constant regions of antibodies that enhance the activity of agonistic antibodies, Chinese patent application number: 201710429281.6, PCT/CN2017/087620
